The Global Antivenom market is poised to have a positive growth rate in the coming years, mainly due to the growing awareness and advancements in research studies.
Snake bite is a neglected public health issue in many tropical and subtropical countries. About 5 million snake bites occur each year, resulting in up to 2.5 million envenoming’s (poisoning from snake bites), at least 100 000 deaths and around three times as many amputations and other permanent disabilities.
Recent studies of pharmacokinetics of envenoming permitted improved understanding of immunotherapy. Improved purification of the antivenom by using immunoglobulin fragments has led to increased tolerance and efficiency of antivenoms. The immunisation procedures and purification and use of IgG fragments for use in antivenoms development can be improved further using modern technology. The detection of specific venom antigens in the blood using immunologically-based techniques, such as enzyme immunoassay helps to identify the specific species to treat the victim conveniently.
The global antivenoms market is segmented based on their nature into monovalent (neutralises the venom of only one species of snake) and polyvalent/polyspecific (neutralises the venoms of several different species), and based on the type of animals it is segmented as Antivenoms for snakebites, Scorpions Spiders and other venomous species. Furthermore, based on geography it is segmented under Asia-Pacific, Europe, North America and Latin America regions.
Most of these occur in Africa, Asia and Latin America. In Africa alone there are an estimated 1 million snake bites annually with about half needing treatment. This are often found among women, children and farmers in poor rural communities in low- and middle-income countries.
With the recent advancements in the R&D division of pharmaceutical sector and also the increase in funding there is an adequate opportunity for the major players in the market to develop antivenoms for broad range of species. And also the rising awareness among the people and increase in the healthcare spending drive the market forward.
Significant challenge in manufacturing of antivenoms is the preparation of the correct immunogens (snake venoms). At present very few countries produce snake venoms of adequate quality for antivenom manufacture. In addition, lack of regulatory capacity for the control of antivenoms in countries results in an inability to assess the quality and appropriateness of the antivenoms. Health systems in many countries lack the infrastructure and resources to collect robust statistical data on the problem. Poor data results in the under-estimation of antivenom needs by national health authorities leading to low demand for manufacturers to produce antivenom products
Some of the key participants in the global antivenom market include Pfizer, Instituto Bioclon, S.A. de C.V., CSL, Roche, Sanofi Pasteur, Merck & Co, Johnson & Johnson etc.
Key Deliverables in the Study?
Market Definition for the Global Antivenoms Market along with identification of key drivers and restraints for the market.
Market analysis for the Global Antivenoms Market, with region specific assessments and competition analysis on a global and regional scale.
Identification of factors instrumental in changing the market scenarios, rising prospective opportunities and identification of key companies which can influence the market on a global and regional scale.
Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market shares.
Identification and analysis of the Macro and Micro factors that affect the Global Antivenoms Market on both global and regional scale.
A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.